|1.||Branch, Robert A: 2 articles (02/2011 - 09/2006)|
|2.||Zhang, Ran-Ran: 1 article (01/2015)|
|3.||Ueno, Yasuharu: 1 article (01/2015)|
|4.||Taniguchi, Hideki: 1 article (01/2015)|
|5.||Tsuchida, Tomonori: 1 article (01/2015)|
|6.||Nie, Yun-Zhong: 1 article (01/2015)|
|7.||Li, Bin: 1 article (01/2015)|
|8.||Zheng, Yun-Wen: 1 article (01/2015)|
|9.||Buch, Shama C: 1 article (02/2011)|
|10.||Stewart, Nicolas A: 1 article (02/2011)|
|1.||Hypertension (High Blood Pressure)
02/01/1976 - "The conclusion was that both drugs were equally effective in the doses studied and well tolerated and that debrisoquine is of value in the treatment of moderate hypertension."
01/01/1999 - "The study was conducted on 10 patients of both sexes with mild to severe essential hypertension, aged 28 to 76 years, with normal hepatic and renal function and phenotyped as extensive metabolizers of debrisoquine (urine debrisoquine to 4-hydroxydebrisoquine ratios of 0.28 to 6.56). "
11/01/1983 - "Therefore, these components were evaluated in 11 normal subjects and 13 patients with mild essential hypertension before and after 4 weeks of sympathetic neuron blockade with the agent debrisoquine. "
08/28/1979 - "[Clinical assay of a debrisoquine-diuretic compound when treating moderate arterial hypertension (author's transl)]."
01/01/1977 - "[Treatment of hypertension with the preparation Tendor]."
|2.||Lung Neoplasms (Lung Cancer)
08/01/1990 - "Overall, individuals who were extensive metabolizers of debrisoquine were at significantly greater risk of lung cancer than those who were poor or intermediate metabolizers (odds ratio = 6.1; 95% confidence interval = 2.2-17.1). "
01/01/1995 - "We examined the hypothesis that the genetically determined ability to metabolize debrisoquine identifies individuals at increased risk for lung cancer in a study designed to address some of the methodological criticisms of previous studies. "
07/01/1991 - "These data suggest that debrisoquine can be administered safely in a controlled clinical setting and will be useful for the characterization of lung cancer patients in biochemical epidemiology studies."
05/01/1997 - "Previous reports of the association between the debrisoquine polymorphism and lung cancer risk are conflicting. "
01/01/1995 - "While the concept that polymorphisms of metabolism may account for differential susceptibility to lung cancer is sound, debrisoquine metabolic phenotype was not associated with lung cancer risk in these data."
|3.||Parkinson Disease (Parkinson's Disease)
01/01/1996 - "Debrisoquine hydroxylation genotype in familial forms of idiopathic Parkinson's disease."
02/24/1995 - "Moreover, 'poor debrisoquine metabolizer' phenotype is significantly increased in Parkinson's disease patients. "
08/01/1992 - "Debrisoquine (DBQ) metabolism was studied in 80 Parkinson's disease (PD) patients, 26 of whom had young onset Parkinson's disease (YOPD), and in 143 controls. "
08/01/1992 - "Debrisoquine hydroxylation in Parkinson's disease."
04/25/1992 - "Mutant debrisoquine hydroxylation genes in Parkinson's disease."
|4.||Body Weight (Weight, Body)
01/01/1994 - "The trials were performed in 15 male healthy volunteers (age 21-25 years, body weight 62-94 kg, body height 172-187 cm) with known N-acetylation and debrisoquine type hydroxylation phenotype. "
09/01/1978 - "Body weight, blood volume, hematocrit and plasma sodium and potassium did not change significantly under debrisoquin while there was a slight but just significant increase in plasma volume. "
03/01/1994 - "These results show that the ability to metabolize debrisoquine is not induced by the presence of a primary lung tumor."
03/01/1994 - "Because lung tumors may produce a variety of humoral substances, we wanted to determine whether the tumor induced debrisoquine metabolism. "
03/01/1994 - "Lung tumor resection does not affect debrisoquine metabolism."
01/01/1989 - "This paper reviews the work carried out by the author and his colleagues which has sought to determine the relative risk of various cancers and related conditions in extensive (EM) and poor (PM) metabolizer phenotypes which arise from the P450IID-mediated 4-hydroxylation of debrisoquine. "
10/15/1987 - "Acetylation phenotype and debrisoquine urinary recovery ratio were not associated with increased risk of nonaggressive cancer. "
|3.||Cytochrome P-450 CYP2D6 (CYP2D6)
|4.||Cytochrome P-450 Enzyme System (Cytochrome P450)
|9.||Caffeine (No Doz)
|1.||Stem Cell Transplantation
|2.||Transplantation (Transplant Recipients)
|3.||Renal Dialysis (Hemodialysis)
|4.||Drug Therapy (Chemotherapy)